Search

Your search keyword '"Nadalin S"' showing total 882 results
Start Over Author "Nadalin S"
882 results on '"Nadalin S"'

2. Glutathione-S-transferase subtypes α and π as a tool to predict and monitor graft failure or regeneration in a pilot study of living donor liver transplantation

Author

Jochum C, Beste M, Sowa J-P, Farahani MS, Penndorf V, Nadalin S, Saner F, Canbay A, and Gerken G

Subjects
living donor liver transplantation, liver regeneration, glutathione-S-transferase α and π, chole stasis, Medicine
Abstract

Abstract Objective Glutathione-S-Transferase (GST) subtype α and π are differentially expressed in adult liver tissue. Objective of the study was if GST α and p may serve as predictive markers for liver surgery, especially transplantations. Methods 13 patients receiving living donor liver transplantation (LDLT) and their corresponding donors were analyzed for standard serum parameters (ALT, AST, gGT, bilirubin) as well as GST-α and -π before LDLT and daily for 10 days after LDLT. Patients (R) and donors (D) were grouped according to graft loss (R1/D1) or positive outcome (R2/D2) and above named serum parameters were compared between the groups. Results R1 showed significantly increased GST-α and significantly lower GST-π levels than R2 patients or the donors. There was a positive correlation between GST-α and ALT, AST as well as bilirubin and a negative correlation to γGT. However, γGT correlated positively with GST-π. Graft failure was associated with combined low GST-π levels in donors and their recipients before living donor liver transplantation. Conclusion Our data suggest that high GST-α serum levels reflect ongoing liver damage while GST-P indicates the capacity and process of liver regeneration. Additionally, GST-π may be useful as marker for optimizing donor and recipient pairs in living donor liver transplantation.

Published
2011
Full Text
View/download PDF

3. A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program

Author

Tieken, I., Haasnoot, G., van Meel, M., Rump, L.C., Rosenkranz, A., Horn, S., Margreiter, R., Schneeberger, S., Oberbauer, R., Pohanka, E., Függer, F., Mühlbacher, F., Berlakovich, G., Meurisse, M., Weekers, L., Ysebaert, D., Wissing, K.M., Mikhalski, D., Mourad, M., van Biesen, W., Kuypers, D., Floege, J., Anthuber, M., Viebahn, R., Schenker, P., Budde, K., Pratschke, J., Zidek, W., Melchior, S., Woitas, R., Strassburg, C.H., Hugo, C., Wirth, M., Schiffer, M., Kribben, A., Pisarski, P., Fichtner-Feigl, S., Haubitz, M., Weimer, R., Weithofer, P., Fornara, P., Fisher, L., Sester, U., Zeier, M., Kliem, V., Klempnauer, l, Grimm, M.O., Kunzendorf, U., Stippel, D., Arns, W., Mönch, C., Nitschke, M., Bartels, M., Krämer, B., Kruger, B., Heemann, U., Werner, J., Hoyer, J., Wolters, H.H., Suwelack, B., Lutz, J., Banas, B., Hakenberg, O., Olbricht, C.J., Kalus, M., Schwenger, V., Nadalin, S., Schröppel, B., Lopau, K., Seelen, M.A.J., Berger, S.P., de Fijter, J.W., van der Linden, S.J., Christiaans, M.H.L., van de Wetering, J., van Zuilen, A.D., Bemelman, F., Nurmohamed, A., Hilbrands, L., de Fijter, Johan, Dreyer, Geertje, Mallat, Marko, Budde, Klemens, Pratschke, Johann, Klempnauer, Jürgen, Zeier, Martin, Arns, Wolfgang, Hugo, Christian, Rump, Lars-Christian, Hauser, Ingeborg, Schenker, Peter, Schiffer, Mario, Grimm, Marc-Oliver, Kliem, Volker, Olbricht, Christoph J., Pisarski, Przemyslaw, Banas, Bernhard, Suwelack, Barbara, Hakenberg, Oliver, Berlakovich, Gabriela, Schneeberger, Stefan, van de Wetering, Jacqueline, Berger, Stefan, Bemelman, Frederike, Kuypers, Dirk, Heidt, Sebastiaan, Rahmel, Axel, Claas, Frans, Peeters, Patrick, Oberbauer, Rainer, Heemann, Uwe, and Krämer, Bernhard K.

Published
2023
Full Text
View/download PDF

8. Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement

Author

Carbone, M, Della Penna, A, Mazzarelli, C, De Martin, E, Villard, C, Bergquist, A, Line, P, Neuberger, J, Al-Shakhshir, S, Trivedi, P, Baumann, U, Cristoferi, L, Hov, J, Fischler, B, Hadzic, N, Debray, D, D'Antiga, L, Selzner, N, Belli, L, Nadalin, S, Carbone M., Della Penna A., Mazzarelli C., De Martin E., Villard C., Bergquist A., Line P. D., Neuberger J. M., Al-Shakhshir S., Trivedi P. J., Baumann U., Cristoferi L., Hov J., Fischler B., Hadzic N. H., Debray D., D'Antiga L., Selzner N., Belli L. S., Nadalin S., Carbone, M, Della Penna, A, Mazzarelli, C, De Martin, E, Villard, C, Bergquist, A, Line, P, Neuberger, J, Al-Shakhshir, S, Trivedi, P, Baumann, U, Cristoferi, L, Hov, J, Fischler, B, Hadzic, N, Debray, D, D'Antiga, L, Selzner, N, Belli, L, Nadalin, S, Carbone M., Della Penna A., Mazzarelli C., De Martin E., Villard C., Bergquist A., Line P. D., Neuberger J. M., Al-Shakhshir S., Trivedi P. J., Baumann U., Cristoferi L., Hov J., Fischler B., Hadzic N. H., Debray D., D'Antiga L., Selzner N., Belli L. S., and Nadalin S.

Abstract

Primary sclerosing cholangitis (PSC) is the classical hepatobiliary manifestation of inflammatory bowel disease (IBD) and a lead indication for liver transplantation (LT) in the western world. In this article, we present a Consensus Statement on LT practice, developed by a dedicated Guidelines’ Taskforce of the European Society of Organ Transplantation (ESOT). The overarching goal is to provide practical guidance on commonly debated topics, including indications and timing of LT, management of bile duct stenosis in patients on the transplant waiting list, technical aspects of transplantation, immunosuppressive strategies post-transplant, timing and extension of intestinal resection and futility criteria for re-transplantation.

Published
2023

9. Liver Transplantation for Primary Sclerosing Cholangitis (PSC) With or Without Inflammatory Bowel Disease (IBD)—A European Society of Organ Transplantation (ESOT) Consensus Statement

Author

Carbone, M., primary, Della Penna, A., additional, Mazzarelli, C., additional, De Martin, E., additional, Villard, C., additional, Bergquist, A., additional, Line, P. D., additional, Neuberger, J. M., additional, Al-Shakhshir, S., additional, Trivedi, P. J., additional, Baumann, U., additional, Cristoferi, L., additional, Hov, J., additional, Fischler, B., additional, Hadzic, N. H., additional, Debray, D., additional, D’Antiga, L., additional, Selzner, N., additional, Belli, L. S., additional, and Nadalin, S., additional

Published
2023
Full Text
View/download PDF

11. A paired-kidney allocation study found superior survival with HLA-DR compatible kidney transplants in the Eurotransplant Senior Program

Author

de Fijter, Johan, primary, Dreyer, Geertje, additional, Mallat, Marko, additional, Budde, Klemens, additional, Pratschke, Johann, additional, Klempnauer, Jürgen, additional, Zeier, Martin, additional, Arns, Wolfgang, additional, Hugo, Christian, additional, Rump, Lars-Christian, additional, Hauser, Ingeborg, additional, Schenker, Peter, additional, Schiffer, Mario, additional, Grimm, Marc-Oliver, additional, Kliem, Volker, additional, Olbricht, Christoph J., additional, Pisarski, Przemyslaw, additional, Banas, Bernhard, additional, Suwelack, Barbara, additional, Hakenberg, Oliver, additional, Berlakovich, Gabriela, additional, Schneeberger, Stefan, additional, van de Wetering, Jacqueline, additional, Berger, Stefan, additional, Bemelman, Frederike, additional, Kuypers, Dirk, additional, Heidt, Sebastiaan, additional, Rahmel, Axel, additional, Claas, Frans, additional, Peeters, Patrick, additional, Oberbauer, Rainer, additional, Heemann, Uwe, additional, Krämer, Bernhard K., additional, Tieken, I., additional, Haasnoot, G., additional, van Meel, M., additional, Rump, L.C., additional, Rosenkranz, A., additional, Horn, S., additional, Margreiter, R., additional, Schneeberger, S., additional, Oberbauer, R., additional, Pohanka, E., additional, Függer, F., additional, Mühlbacher, F., additional, Berlakovich, G., additional, Meurisse, M., additional, Weekers, L., additional, Ysebaert, D., additional, Wissing, K.M., additional, Mikhalski, D., additional, Mourad, M., additional, van Biesen, W., additional, Kuypers, D., additional, Floege, J., additional, Anthuber, M., additional, Viebahn, R., additional, Schenker, P., additional, Budde, K., additional, Pratschke, J., additional, Zidek, W., additional, Melchior, S., additional, Woitas, R., additional, Strassburg, C.H., additional, Hugo, C., additional, Wirth, M., additional, Schiffer, M., additional, Kribben, A., additional, Pisarski, P., additional, Fichtner-Feigl, S., additional, Haubitz, M., additional, Weimer, R., additional, Weithofer, P., additional, Fornara, P., additional, Fisher, L., additional, Sester, U., additional, Zeier, M., additional, Kliem, V., additional, Klempnauer, l, additional, Grimm, M.O., additional, Kunzendorf, U., additional, Stippel, D., additional, Arns, W., additional, Mönch, C., additional, Nitschke, M., additional, Bartels, M., additional, Krämer, B., additional, Kruger, B., additional, Heemann, U., additional, Werner, J., additional, Hoyer, J., additional, Wolters, H.H., additional, Suwelack, B., additional, Lutz, J., additional, Banas, B., additional, Hakenberg, O., additional, Olbricht, C.J., additional, Kalus, M., additional, Schwenger, V., additional, Nadalin, S., additional, Schröppel, B., additional, Lopau, K., additional, Seelen, M.A.J., additional, Berger, S.P., additional, de Fijter, J.W., additional, van der Linden, S.J., additional, Christiaans, M.H.L., additional, van de Wetering, J., additional, van Zuilen, A.D., additional, Bemelman, F., additional, Nurmohamed, A., additional, and Hilbrands, L., additional

Published
2023
Full Text
View/download PDF

17. Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries

Author

Linschoten, M, Uijl, A, Schut, A, Jakob, CEM, Romao, LR, Bell, RM, McFarlane, E, Stecher, M, Zondag, AGM, van Iperen, EPA, Hermans-van Ast, JF, Lea, NC, Schaap, J, Jewbali, LS, Smits, PC, Patel, RS, Aujayeb, A, van Smeden, M, Siebelink, HJ, Williams, S, Pilgram, L, Tieleman, RG, Williams, B, Asselbergs, FW, Al-Ali, AK, Al-Muhanna, FA, Al-Rubaish, AM, Al-Windy, NYY, Alkhalil, M, Almubarak, YA, Al Nafie, AN, Al Shahrani, M, Al Shehri, AM, Anning, C, Anthonio, RL, Badings, EA, Ball, C, Van Beek, EA, Ten Berg, JM, Von Bergwelt-Baildon, M, Bianco, M, Blagova, O, Bleijendaal, H, Bor, WL, Borgmann, S, van Boxem, AJM, van den Brink, FS, Bucciarelli-Ducci, C, Van Bussel, BCT, Byrom-Goulthorp, R, Captur, G, Caputo, M, Charlotte, N, vom Dahl, J, Dark, P, De Sutter, J, Degenhardt, C, Delsing, CE, Dolff, S, Dorman, HGR, Drost, JT, Eberwein, L, Emans, ME, Er, AG, Ferreira, JB, Forner, MJ, Friedrichs, A, Gabriel, L, Groenemeijer, BE, Groenendijk, AL, Gruener, B, Guggemos, W, Haerkens-Arends, HE, Hanses, F, Hedayat, B, Heigener, D, van der Heijden, DJ, Hellou, E, Hellwig, K, Henkens, MTHM, Hermanides, RS, Hermans, WRM, van Hessen, MWJ, Heymans, SRB, Hilt, AD, van der Horst, ICC, Hower, M, van Ierssel, SH, Isberner, N, Jensen, B, Kearney, MT, Kielstein, JT, Kietselaer, BLJH, Kochanek, M, Kolk, MZH, Koning, AMH, Kopylov, PY, Kuijper, AFM, Kwakkel-van, ERPJM, Lanznaster, J, van der Linden, MMJM, van der Lingen, ACJ, Linssen, GCM, Lomas, D, Maarse, M, Magdelijns, FJH, Magro, M, Markart, P, Martens, FMAC, Mazzilli, SG, McCann, GP, van der Meer, P, Meijs, MFL, Merle, U, Messiaen, P, Milovanovic, M, Monraats, PS, Montagna, L, Moriarty, A, Moss, AJ, Mosterd, A, Nadalin, S, Nattermann, J, Neufang, M, Nierop, PR, Offerhaus, JA, Van Ofwegen-Hanekamp, CEE, Parker, E, Persoon, AM, Piepel, C, Pinto, YM, Poorhosseini, H, Prasad, S, Raafs, AG, Raichle, C, Rauschning, D, Redon, J, Reidinga, AC, Ribeiro, MIA, Riedel, C, Rieg, S, Ripley, DP, Rommele, C, Rothfuss, K, Ruddel, J, Ruthrich, MM, Salah, R, Saneei, E, Saxena, M, Schellings, DAAM, Scholte, NTB, Schubert, J, Seelig, J, Shafiee, A, Shore, AC, Spinner, C, Stieglitz, S, Strauss, R, Sturkenboom, NH, Tessitore, E, Thomson, RJ, Timmermans, PJR, Tio, RA, Tjong, FVY, Tometten, L, Trauth, J, Van Craenenbroeck, EM, van Veen, HPAA, den Uil, CA, Vehreschild, MJGT, Veldhuis, L, Veneman, T, Verschure, DO, Voigt, I, Walter, L, vande Watering, DJ, de Vries, JK, vande Wal, RMA, Westendorp, ICD, Westendorp, PHM, Westhoff, T, Weytjens, C, Wierda, E, Wille, K, de With, K, Worm, M, Woudstra, P, Wu, KW, Zaal, R, Zaman, AG, van der Zee, PM, Zijlstra, LE, Alling, TE, Ahmed, R, Bayraktar-Verver, ECE, van Aken, K, Jimenes, Bermudez FJ, Biole, CA, Den Boer-Penning, P, Bontje, M, Bos, M, Bosch, L, Broekman, M, Broeyer, FJF, de Bruijn, EAW, Bruinsma, S, Cardoso, NM, Cosyns, B, Len, van Da DH, Dekimpe, E, Domange, J, van Doorn, JL, van DOorn, P, Dormal, F, Drost, IMJ, Dunnink, A, van Eck, JWM, Elshinawy, K, Gevers, RMM, Gognieva, DG, van der Graaf, M, Grangeon, S, Guclu, A, Habib, A, Haenen, NA, Hamilton, K, Handgraaf, S, Heidbuchel, H, Hendriks-van Woerden, M, Hessels-Linnemeijer, BM, Hosseini, K, Huisman, J, Jacobs, TC, Jansen, SE, Janssen, A, Jourdan, K, ten Kate, GL, van Kempen, MJ, Kievit, CM, Kleikers, P, Knufman, N, van der Kooi, SE, Koole, BAS, Koole, MAC, Kui, KK, Kuipers-Elferink, L, Lemoine, I, Lensink, E, van Marrewijk, V, Meijer, EJ, Melein, AJ, Mesitskaya, DF, van Nes, CPM, Paris, FMA, Perrelli, MG, Pieterse-Rots, A, Pisters, R, Polkerman, BC, van Poppel, A, Reinders, S, Reitsma, MJ, Ruiter, AH, Selder, JL, van der Sluis, A, Sousa, AIC, Tajdini, M, Sanchez, Tercedor L, Van de Heyning, CM, Vial, H, Vlieghe, E, Vonkeman, HE, Vreugdenhil, P, de Vries, TAC, Willems, AM, Wils, AM, Zoet-Nugteren, SK, Cardiovascular Centre (CVC), Restoring Organ Function by Means of Regenerative Medicine (REGENERATE), Cardiology, Intensive Care, RS: CAPHRI - R5 - Optimising Patient Care, MUMC+: MA Medische Staf IC (9), RS: Carim - H02 Cardiomyopathy, Cardiologie, MUMC+: MA Med Staf Spec Cardiologie (9), RS: Carim - V04 Surgical intervention, MUMC+: MA Intensive Care (3), UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de cardiologie, CAPACITY-COVID Collaborative Consortium, LEOSS Study Group, Rheumatology, AII - Infectious diseases, AII - Inflammatory diseases, AMS - Musculoskeletal Health, AMS - Tissue Function & Regeneration, ACS - Heart failure & arrhythmias, General practice, Epidemiology and Data Science, Graduate School, Nuclear Medicine, and ACS - Atherosclerosis & ischemic syndromes

Subjects
Male, Cardiac & Cardiovascular Systems, Epidemiology, education, Medizin, Comorbidity, AMERICAN-COLLEGE, GUIDELINES, DIAGNOSIS, Cohort Studies, Risk Factors, MANAGEMENT, Humans, AcademicSubjects/MED00200, Hospital Mortality, Aged, Heart Failure, Science & Technology, SARS-CoV-2, COVID-19, ASSOCIATION, Cardiovascular disease, EUROPEAN-SOCIETY, Hospitalization, surgical procedures, operative, Editorial, Cardiovascular System & Cardiology, behavior and behavior mechanisms, HEART-FAILURE, Female, Patient registry, Human medicine, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, psychological phenomena and processes, TASK-FORCE
Abstract

Aims Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality. Methods and results We used data from the CAPACITY-COVID registry and LEOSS study. Multivariable Poisson regression models were fitted to assess the association between different types of pre-existing heart disease and in-hospital mortality. A total of 16 511 patients with COVID-19 were included (21.1% aged 66–75 years; 40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly male, and often had other comorbid conditions when compared with those without. Mortality was higher in patients with cardiac disease (29.7%; n = 1545 vs. 15.9%; n = 1797). However, following multivariable adjustment, this difference was not significant [adjusted risk ratio (aRR) 1.08, 95% confidence interval (CI) 1.02–1.15; P = 0.12 (corrected for multiple testing)]. Associations with in-hospital mortality by heart disease subtypes differed considerably, with the strongest association for heart failure (aRR 1.19, 95% CI 1.10–1.30; P Conclusion Considerable heterogeneity exists in the strength of association between heart disease subtypes and in-hospital mortality. Of all patients with heart disease, those with heart failure are at greatest risk of death when hospitalized with COVID-19. Serious cardiac complications are rare during hospitalization.

Published
2021

19. Hepatocellular carcinoma progression during bridging before liver transplantation

Author

Renner, P, Da Silva, T, Schnitzbauer, A, Verloh, N, Schlitt, H, Geissler, E, Zulke, C, Lamby, P, Proneth, A, Duvoux, C, Burra, P, Jauch, K, Rentsch, M, Ganten, T, Schmidt, J, Settmacher, U, Heise, M, Rossi, G, Cillo, U, Kneteman, N, Adam, R, Van Hoek, B, Bachellier, P, Wolf, P, Rostaing, L, Bechstein, W, Rizell, M, Powell, J, Hidalgo, E, Gugenheim, J, Wolters, H, Brockmann, J, Roy, A, Mutzbauer, I, Schlitt, A, Beckebaum, S, Graeb, C, Nadalin, S, Valente, U, Sanchez Turrion, V, Jamieson, N, Scholz, T, Colledan, M, Fandrich, F, Becker, T, Soderdahl, G, Chazouilleres, O, Makisalo, H, Pageaux, G, Steininger, R, Soliman, T, De Jong, K, Pirenne, J, Margreiter, R, Pratschke, J, Pinna, A, Hauss, J, Schreiber, S, Strasser, S, Klempnauer, J, Troisi, R, Bhoori, S, Lerut, J, Bilbao, I, Klein, C, Konigsrainer, A, Otto, G, Mazzaferro, V, Neuhaus, P, Renner P., Da Silva T., Schnitzbauer A. A., Verloh N., Schlitt H. J., Geissler E. K., Zulke C., Lamby P. E., Proneth A., Duvoux C., Burra P., Jauch K. -W., Rentsch M., Ganten T. M., Schmidt J., Settmacher U., Heise M., Rossi G., Cillo U., Kneteman N., Adam R., Van Hoek B., Bachellier P., Wolf P., Rostaing L., Bechstein W. O., Rizell M., Powell J., Hidalgo E., Gugenheim J., Wolters H., Brockmann J., Roy A., Mutzbauer I., Schlitt A., Beckebaum S., Graeb C., Nadalin S., Valente U., Sanchez Turrion V., Jamieson N., Scholz T., Colledan M., Fandrich F., Becker T., Soderdahl G., Chazouilleres O., Makisalo H., Pageaux G. -P., Steininger R., Soliman T., De Jong K. P., Pirenne J., Margreiter R., Pratschke J., Pinna A. D., Hauss J., Schreiber S., Strasser S., Klempnauer J., Troisi R. I., Bhoori S., Lerut J., Bilbao I., Klein C. G., Konigsrainer A., Otto G., Mazzaferro V., Neuhaus P., Renner, P, Da Silva, T, Schnitzbauer, A, Verloh, N, Schlitt, H, Geissler, E, Zulke, C, Lamby, P, Proneth, A, Duvoux, C, Burra, P, Jauch, K, Rentsch, M, Ganten, T, Schmidt, J, Settmacher, U, Heise, M, Rossi, G, Cillo, U, Kneteman, N, Adam, R, Van Hoek, B, Bachellier, P, Wolf, P, Rostaing, L, Bechstein, W, Rizell, M, Powell, J, Hidalgo, E, Gugenheim, J, Wolters, H, Brockmann, J, Roy, A, Mutzbauer, I, Schlitt, A, Beckebaum, S, Graeb, C, Nadalin, S, Valente, U, Sanchez Turrion, V, Jamieson, N, Scholz, T, Colledan, M, Fandrich, F, Becker, T, Soderdahl, G, Chazouilleres, O, Makisalo, H, Pageaux, G, Steininger, R, Soliman, T, De Jong, K, Pirenne, J, Margreiter, R, Pratschke, J, Pinna, A, Hauss, J, Schreiber, S, Strasser, S, Klempnauer, J, Troisi, R, Bhoori, S, Lerut, J, Bilbao, I, Klein, C, Konigsrainer, A, Otto, G, Mazzaferro, V, Neuhaus, P, Renner P., Da Silva T., Schnitzbauer A. A., Verloh N., Schlitt H. J., Geissler E. K., Zulke C., Lamby P. E., Proneth A., Duvoux C., Burra P., Jauch K. -W., Rentsch M., Ganten T. M., Schmidt J., Settmacher U., Heise M., Rossi G., Cillo U., Kneteman N., Adam R., Van Hoek B., Bachellier P., Wolf P., Rostaing L., Bechstein W. O., Rizell M., Powell J., Hidalgo E., Gugenheim J., Wolters H., Brockmann J., Roy A., Mutzbauer I., Schlitt A., Beckebaum S., Graeb C., Nadalin S., Valente U., Sanchez Turrion V., Jamieson N., Scholz T., Colledan M., Fandrich F., Becker T., Soderdahl G., Chazouilleres O., Makisalo H., Pageaux G. -P., Steininger R., Soliman T., De Jong K. P., Pirenne J., Margreiter R., Pratschke J., Pinna A. D., Hauss J., Schreiber S., Strasser S., Klempnauer J., Troisi R. I., Bhoori S., Lerut J., Bilbao I., Klein C. G., Konigsrainer A., Otto G., Mazzaferro V., and Neuhaus P.

Abstract

Background: Recipient selection for liver transplantation in hepatocellular carcinoma (HCC) is based primarily on criteria affecting the chance of long-term success. Here, the relationship between pretransplant bridging therapy and long-term survival was investigated in a subgroup analysis of the SiLVER Study. Methods: Response to bridging, as defined by comparison of imaging at the time of listing and post-transplant pathology report, was categorized into controlled versus progressive disease (more than 20 per cent tumour growth or development of new lesions). Results: Of 525 patients with HCC who had liver transplantation, 350 recipients underwent pretransplant bridging therapy. Tumour progression despite bridging was an independent risk factor affecting overall survival (hazard ratio 1.80; P=0.005). For patients within the Milan criteria (MC) at listing, mean overall survival was longer for those with controlled versus progressive disease (6.8 versus 5.8 years; P<0.001). Importantly, patients with HCCs outside the MC that were downsized to within the MC before liver transplantation had poor outcomes compared with patients who never exceeded the MC (mean overall survival 6.2 versus 6.6 years respectively; P=0.030). Conclusion: Patients with HCCs within the MC that did not show tumour progression under locoregional therapy had the best outcomes after liver transplantation. Downstaging into the limits of the MC did not improve the probability of survival. Prognostic factors determining the long-term success of liver transplantation in patients with hepatocellular carcinoma are still under discussion. A subgroup analysis of the SiLVER trial showed that disease control under bridging therapy is strongly associated with improved prognosis in terms of overall survival. However, in tumours exceeding the limits of the Milan criteria, downstaging did not restore the probability of survival compared with that of patients within the Milan criteria.

Published
2021

21. mTOR Inhibition Is Most Beneficial After Liver Transplantation for Hepatocellular Carcinoma in Patients With Active Tumors

Author

Schnitzbauer, A, Filmann, N, Adam, R, Bachellier, P, Bechstein, W, Becker, T, Bhoori, S, Bilbao, I, Brockmann, J, Burra, P, Chazoullieres, O, Cillo, U, Colledan, M, Duvoux, C, Ganten, T, Gugenheim, J, Heise, M, van Hoek, B, Jamieson, N, de Jong, K, Klein, C, Klempnauer, J, Kneteman, N, Lerut, J, Makisalo, H, Mazzaferro, V, Mirza, D, Nadalin, S, Neuhaus, P, Pageaux, G, Pinna, A, Pirenne, J, Pratschke, J, Powel, J, Rentsch, M, Rizell, M, Rossi, G, Rostaing, L, Roy, A, Scholz, T, Settmacher, U, Soliman, T, Strasser, S, Soderdahl, G, Troisi, R, Turrion, V, Schlitt, H, Geissler, E, Schnitzbauer AA, Filmann N, Adam RP, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, Burra P, Chazoullieres O, Cillo U, Colledan M, Duvoux C, Ganten TM, Gugenheim J, Heise M, van Hoek B, Jamieson N, de Jong KP, Klein CG, Klempnauer J, Kneteman N, Lerut J, Makisalo H, Mazzaferro V, Mirza DF, Nadalin S, Neuhaus P, Pageaux GP, Pinna AD, Pirenne J, Pratschke J, Powel J, Rentsch M, Rizell M, Rossi G, Rostaing L, Roy AP, Scholz T, Settmacher U, Soliman T, Strasser S, Soderdahl G, Troisi RI, Turrion VS, Schlitt HJ, Geissler EK, Schnitzbauer, A, Filmann, N, Adam, R, Bachellier, P, Bechstein, W, Becker, T, Bhoori, S, Bilbao, I, Brockmann, J, Burra, P, Chazoullieres, O, Cillo, U, Colledan, M, Duvoux, C, Ganten, T, Gugenheim, J, Heise, M, van Hoek, B, Jamieson, N, de Jong, K, Klein, C, Klempnauer, J, Kneteman, N, Lerut, J, Makisalo, H, Mazzaferro, V, Mirza, D, Nadalin, S, Neuhaus, P, Pageaux, G, Pinna, A, Pirenne, J, Pratschke, J, Powel, J, Rentsch, M, Rizell, M, Rossi, G, Rostaing, L, Roy, A, Scholz, T, Settmacher, U, Soliman, T, Strasser, S, Soderdahl, G, Troisi, R, Turrion, V, Schlitt, H, Geissler, E, Schnitzbauer AA, Filmann N, Adam RP, Bachellier P, Bechstein WO, Becker T, Bhoori S, Bilbao I, Brockmann J, Burra P, Chazoullieres O, Cillo U, Colledan M, Duvoux C, Ganten TM, Gugenheim J, Heise M, van Hoek B, Jamieson N, de Jong KP, Klein CG, Klempnauer J, Kneteman N, Lerut J, Makisalo H, Mazzaferro V, Mirza DF, Nadalin S, Neuhaus P, Pageaux GP, Pinna AD, Pirenne J, Pratschke J, Powel J, Rentsch M, Rizell M, Rossi G, Rostaing L, Roy AP, Scholz T, Settmacher U, Soliman T, Strasser S, Soderdahl G, Troisi RI, Turrion VS, Schlitt HJ, and Geissler EK

Abstract

Objective: The aim of this study was to evaluate the survival benefit of sirolimus in patients undergoing liver transplantation (LT) for hepatocellular carcinoma (HCC) (exploratory analysis of the SiLVER-trial). Summary and Background Data: Patients receiving LT) for HCC are at a high risk for tumor recurrence. Calcineurin inhibitors have shown evidence to promote cancer growth, whereas mammalian target of rapamycin (mTOR) inhibitors like sirolimus have anticancer effects. In the SiLVER-trial (Clinicaltrials.gov:NCT00355862), the effect of sirolimus on the recurrence of HCC after LTwas investigated in a prospective randomized trial. Although the primary endpoint of improved disease-free survival (DFS) with sirolimus was not met, outcomes were improved for patients in the sirolimus-treatment arm in the first 3 to 5 years. To learn more about the key variables, a multivariate analysis was performed on the SiLVER-trial data. Patients and Methods: Data from 508 patients of the intention-to-treat analysis were included in exploratory univariate and multivariate models for overall survival (OS), DFS and a competing risk analysis for HCC recurrence. Results: Sirolimus use for >= 3 months after LT for HCC independently reduced the hazard for death in the multivariate analysis [hazard ratio (HR): 0.7 (95% confidence interval, CI: 0.52-0.96, P = 0.02). Most strikingly, patients with an alpha-fetoprotein (AFP) >= 10 ng/mL and having used sirolimus for >= 3 months, benefited most with regard to OS, DFS, and HCC-recurrence (HR: 0.49- 0.59, P = 0.0079- 0.0245). Conclusions: mTOR-inhibitor treatment with sirolimus for >= 3 months improves outcomes in LT for HCC, especially in patients with AFP-evidence of higher tumor activity, advocating particularly for mTOR inhibitor use in this subgroup of patients. Clinical Trial Registration: EudraCT: 2005-005362-36 Clinicaltrials.gov: NCT00355862.

Published
2020

22. Impact of COVID-19 on liver transplantation in Europe: alert from an early survey of European Liver and Intestine Transplantation Association and European Liver Transplant Registry

Author

Polak, W, Fondevila, C, Karam, V, Adam, R, Baumann, U, Germani, G, Nadalin, S, Taimr, P, Toso, C, Troisi, R, Zieniewicz, K, Belli, L, Duvoux, C, Polak W. G., Fondevila C., Karam V., Adam R., Baumann U., Germani G., Nadalin S., Taimr P., Toso C., Troisi R. I., Zieniewicz K., Belli L. S., Duvoux C., Polak, W, Fondevila, C, Karam, V, Adam, R, Baumann, U, Germani, G, Nadalin, S, Taimr, P, Toso, C, Troisi, R, Zieniewicz, K, Belli, L, Duvoux, C, Polak W. G., Fondevila C., Karam V., Adam R., Baumann U., Germani G., Nadalin S., Taimr P., Toso C., Troisi R. I., Zieniewicz K., Belli L. S., and Duvoux C.

Abstract

There are scarce data on the impact of COVID-19 pandemic on liver transplantation (LT) in Europe. The aim of this study was to obtain a preliminary data on incidence, management, and outcome of COVID-19 in liver transplant recipients and candidates in Europe. An Internet-based survey was sent to the centers affiliated with European Liver Transplant Registry (ELTR). One hundred nine out of 149 (73%) of ELTR centers located in 28 European countries (93%) responded. Ninety-four (86%) of the centers tested all donors, and 75 (69%) centers tested all LT recipients for SARS-CoV-2. Seventy-three (67%) centers selected recipients for LT in the COVID-19 pandemic, whereas 33% did not. Eighty-eight centers reported COVID-19 infection in 57 LT candidates and in 272 LT recipients. Overall crude incidence of COVID-19 among LT candidates and recipients was estimated 1.05% (range 0.5–20%) and 0.34% (range 0.1–4.8%), respectively, and it was significantly higher among candidates (P ' 0.001). Crude rate of death was 18% (10/57) among candidates and 15% (36/244) among recipients. This first large-scale European snapshot study clearly shows that both LT candidates and recipients are at a high risk for COVID-19. These results plead for an early and pro-active screening of COVID-19 symptoms in these populations.

Published
2020

23. HCC recurrence in HCV-infected patients after liver transplantation: SiLVER Study reveals benefits of sirolimus in combination with CNIs – a post-hoc analysis

Author

Werner, J, Hornung, M, Krah, R, Gotz, M, Schnitzbauer, A, Schlitt, H, Geissler, E, Zulke, C, Lamby, P, Proneth, A, Duvoux, C, Burra, P, Jauch, K, Rentsch, M, Ganten, T, Schmidt, J, Settmacher, U, Heise, M, Rossi, G, Cillo, U, Kneteman, N, Adam, R, Hoek, B, Bachellier, P, Wolf, P, Rostaing, L, Bechstein, W, Rizell, M, Powell, J, Hidalgo, E, Gugenheim, J, Wolters, H, Brockmann, J, Roy, A, Mutzbauer, I, Schlitt, A, Beckebaum, S, Graeb, C, Nadalin, S, Valente, U, Turrion, V, Jamieson, N, Scholz, T, Colledan, M, Fandrich, F, Becker, T, Soderdahl, G, Chazouilleres, O, Makisalo, H, Pageaux, G, Steininger, R, Soliman, T, Jong, K, Pirenne, J, Margreiter, R, Pratschke, J, Pinna, A, Hauss, J, Schreiber, S, Strasser, S, Klempnauer, J, Troisi, R, Bhoori, S, Lerut, J, Bilbao, I, Klein, C, Konigsrainer, A, Otto, G, Mazzaferro, V, Neuhaus, P, Werner J. M., Hornung M., Krah R., Gotz M., Schnitzbauer A. A., Schlitt H. J., Geissler E. K., Zulke C., Lamby P. E., Proneth A., Duvoux C., Burra P., Jauch K. -W., Rentsch M., Ganten T. M., Schmidt J., Settmacher U., Heise M., Rossi G., Cillo U., Kneteman N., Adam R., Hoek B., Bachellier P., Wolf P., Rostaing L., Bechstein W. O., Rizell M., Powell J., Hidalgo E., Gugenheim J., Wolters H., Brockmann J., Roy A., Mutzbauer I., Schlitt A., Beckebaum S., Graeb C., Nadalin S., Valente U., Turrion V. S., Jamieson N., Scholz T., Colledan M., Fandrich F., Becker T., Soderdahl G., Chazouilleres O., Makisalo H., Pageaux G. -P., Steininger R., Soliman T., Jong K. P., Pirenne J., Margreiter R., Pratschke J., Pinna A. D., Hauss J., Schreiber S., Strasser S., Klempnauer J., Troisi R. I., Bhoori S., Lerut J., Bilbao I., Klein C. G., Konigsrainer A., Otto G., Mazzaferro V., Neuhaus P., Werner, J, Hornung, M, Krah, R, Gotz, M, Schnitzbauer, A, Schlitt, H, Geissler, E, Zulke, C, Lamby, P, Proneth, A, Duvoux, C, Burra, P, Jauch, K, Rentsch, M, Ganten, T, Schmidt, J, Settmacher, U, Heise, M, Rossi, G, Cillo, U, Kneteman, N, Adam, R, Hoek, B, Bachellier, P, Wolf, P, Rostaing, L, Bechstein, W, Rizell, M, Powell, J, Hidalgo, E, Gugenheim, J, Wolters, H, Brockmann, J, Roy, A, Mutzbauer, I, Schlitt, A, Beckebaum, S, Graeb, C, Nadalin, S, Valente, U, Turrion, V, Jamieson, N, Scholz, T, Colledan, M, Fandrich, F, Becker, T, Soderdahl, G, Chazouilleres, O, Makisalo, H, Pageaux, G, Steininger, R, Soliman, T, Jong, K, Pirenne, J, Margreiter, R, Pratschke, J, Pinna, A, Hauss, J, Schreiber, S, Strasser, S, Klempnauer, J, Troisi, R, Bhoori, S, Lerut, J, Bilbao, I, Klein, C, Konigsrainer, A, Otto, G, Mazzaferro, V, Neuhaus, P, Werner J. M., Hornung M., Krah R., Gotz M., Schnitzbauer A. A., Schlitt H. J., Geissler E. K., Zulke C., Lamby P. E., Proneth A., Duvoux C., Burra P., Jauch K. -W., Rentsch M., Ganten T. M., Schmidt J., Settmacher U., Heise M., Rossi G., Cillo U., Kneteman N., Adam R., Hoek B., Bachellier P., Wolf P., Rostaing L., Bechstein W. O., Rizell M., Powell J., Hidalgo E., Gugenheim J., Wolters H., Brockmann J., Roy A., Mutzbauer I., Schlitt A., Beckebaum S., Graeb C., Nadalin S., Valente U., Turrion V. S., Jamieson N., Scholz T., Colledan M., Fandrich F., Becker T., Soderdahl G., Chazouilleres O., Makisalo H., Pageaux G. -P., Steininger R., Soliman T., Jong K. P., Pirenne J., Margreiter R., Pratschke J., Pinna A. D., Hauss J., Schreiber S., Strasser S., Klempnauer J., Troisi R. I., Bhoori S., Lerut J., Bilbao I., Klein C. G., Konigsrainer A., Otto G., Mazzaferro V., and Neuhaus P.

Abstract

Factors affecting outcomes in liver transplant (LTx) recipients with hepatocellular carcinoma (HCC) and hepatitis C viral (HCV) infection include the choice of immunosuppression. Here, we analyzed the HCV+ subgroup of patients from the randomized controlled, international SiLVER Study. We performed a post hoc analysis of 166 HCV+ SiLVER Study patients regarding HCC outcome after LTx. Control patients (group A: n = 88) received mTOR inhibitor (mTORi)-free, calcineurin inhibitor (CNI)-based versus sirolimus-based immunosuppression (group B: n = 78). We found no significant difference regarding HCV-RNA titers between group A and B. Since no effect in group B could be due to variable sirolimus dosing, we split group B into patients receiving sirolimus-based immunosuppression + CNIs for >50% (B1; n = 44) or <50% (B2; n = 34) of the time. While there remained no difference in HCV-RNA titer between groups, HCC recurrence-free survival in group B1 (81.8%) was markedly better versus both group A (62.7%; P = 0.0136) and group B2 (64.7%; P = 0.0326); Interestingly, further subgroup analysis revealed an increase (P = 0.0012) in liver enzyme values in group B2. Taken together, in HCV-infected patients with HCC and LTx, mTORi immunosuppression + CNIs yields excellent outcomes. Unexpectedly, higher levels of liver inflammation and poorer outcomes occur with mTORi monotherapy in the HCV+ subgroup.

Published
2020

25. Clinical presentation, disease course, and outcome of COVID-19 in hospitalized patients with and without pre-existing cardiac disease: a cohort study across 18 countries

Author

Linschoten, M., Uijl, A., Schut, A., Jakob, C. E. M., Romao, L. R., Bell, R. M., McFarlane, E., Stecher, M., Zondag, A. G. M., van Iperen, E. P. A., Hermans-van Ast, J. F., Lea, N. C., Schaap, J., Jewbali, L. S., Smits, P. C., Patel, R. S., Aujayeb, A., van Smeden, M., Siebelink, H. J., Williams, S., Pilgram, L., Tieleman, R. G., Williams, B., Asselbergs, F. W., Al-Ali, A. K., Al-Muhanna, F. A., Al-Rubaish, A. M., Al-Windy, N. Y. Y., Alkhalil, M., Almubarak, Y. A., Al Nafie, A. N., Al Shahrani, M., Al Shehri, A. M., Anning, C., Anthonio, R. L., Badings, E. A., Ball, C., Van Beek, E. A., Ten Berg, J. M., Von Bergwelt-Baildon, M., Bianco, M., Blagova, O., V, Bleijendaal, H., Bor, W. L., Borgmann, S., van Boxem, A. J. M., van den Brink, F. S., Bucciarelli-Ducci, C., Van Bussel, B. C. T., Byrom-Goulthorp, R., Captur, G., Caputo, M., Charlotte, N., vom Dahl, J., Dark, P., De Sutter, J., Degenhardt, C., Delsing, C. E., Dolff, S., Dorman, H. G. R., Drost, J. T., Eberwein, L., Emans, M. E., Er, A. G., Ferreira, J. B., Forner, M. J., Friedrichs, A., Gabriel, L., Groenemeijer, B. E., Groenendijk, A. L., Gruener, B., Guggemos, W., Haerkens-Arends, H. E., Hanses, F., Hedayat, B., Heigener, D., van der Heijden, D. J., Hellou, E., Hellwig, K., Henkens, M. T. H. M., Hermanides, R. S., Hermans, W. R. M., van Hessen, M. W. J., Heymans, S. R. B., Hilt, A. D., van der Horst, I. C. C., Hower, M., van Ierssel, S. H., Isberner, N., Jensen, B., Kearney, M. T., Kielstein, J. T., Kietselaer, B. L. J. H., Kochanek, M., Kolk, M. Z. H., Koning, A. M. H., Kopylov, P. Y., Kuijper, A. F. M., Kwakkel-van, E. R. P. J. M., Lanznaster, J., van der Linden, M. M. J. M., van der Lingen, A. C. J., Linssen, G. C. M., Lomas, D., Maarse, M., Magdelijns, F. J. H., Magro, M., Markart, P., Martens, F. M. A. C., Mazzilli, S. G., McCann, G. P., van der Meer, P., Meijs, M. F. L., Merle, U., Messiaen, P., Milovanovic, M., Monraats, P. S., Montagna, L., Moriarty, A., Moss, A. J., Mosterd, A., Nadalin, S., Nattermann, J., Neufang, M., Nierop, P. R., Offerhaus, J. A., Van Ofwegen-Hanekamp, C. E. E., Parker, E., Persoon, A. M., Piepel, C., Pinto, Y. M., Poorhosseini, H., Prasad, S., Raafs, A. G., Raichle, C., Rauschning, D., Redon, J., Reidinga, A. C., Ribeiro, M. I. A., Riedel, C., Rieg, S., Ripley, D. P., Rommele, C., Rothfuss, K., Ruddel, J., Ruthrich, M. M., Salah, R., Saneei, E., Saxena, M., Schellings, D. A. A. M., Scholte, N. T. B., Schubert, J., Seelig, J., Shafiee, A., Shore, A. C., Spinner, C., Stieglitz, S., Strauss, R., Sturkenboom, N. H., Tessitore, E., Thomson, R. J., Timmermans, P. J. R., Tio, R. A., Tjong, F. V. Y., Tometten, L., Trauth, J., Van Craenenbroeck, E. M., van Veen, H. P. A. A., den Uil, C. A., Vehreschild, M. J. G. T., Veldhuis, L., I, Veneman, T., Verschure, D. O., Voigt, I, Walter, L., vande Watering, D. J., de Vries, J. K., vande Wal, R. M. A., Westendorp, I. C. D., Westendorp, P. H. M., Westhoff, T., Weytjens, C., Wierda, E., Wille, K., de With, K., Worm, M., Woudstra, P., Wu, K. W., Zaal, R., Zaman, A. G., van der Zee, P. M., Zijlstra, L. E., Alling, T. E., Ahmed, R., Bayraktar-Verver, E. C. E., van Aken, K., Jimenes, Bermudez F. J., Biole, C. A., Den Boer-Penning, P., Bontje, M., Bos, M., Bosch, L., Broekman, M., Broeyer, F. J. F., de Bruijn, E. A. W., Bruinsma, S., Cardoso, N. M., Cosyns, B., Len, van Da D. H., Dekimpe, E., Domange, J., van Doorn, J. L., van DOorn, P., Dormal, F., Drost, I. M. J., Dunnink, A., van Eck, J. W. M., Elshinawy, K., Gevers, R. M. M., Gognieva, D. G., van der Graaf, M., Grangeon, S., Guclu, A., Habib, A., Haenen, N. A., Hamilton, K., Handgraaf, S., Heidbuchel, H., Hendriks-van Woerden, M., Hessels-Linnemeijer, B. M., Hosseini, K., Huisman, J., Jacobs, T. C., Jansen, S. E., Janssen, A., Jourdan, K., ten Kate, G. L., van Kempen, M. J., Kievit, C. M., Kleikers, P., Knufman, N., van der Kooi, S. E., Koole, B. A. S., Koole, M. A. C., Kui, K. K., Kuipers-Elferink, L., Lemoine, I, Lensink, E., van Marrewijk, V, Meijer, E. J., Melein, A. J., Mesitskaya, D. F., van Nes, C. P. M., Paris, F. M. A., Perrelli, M. G., Pieterse-Rots, A., Pisters, R., Polkerman, B. C., van Poppel, A., Reinders, S., Reitsma, M. J., Ruiter, A. H., Selder, J. L., van der Sluis, A., Sousa, A. I. C., Tajdini, M., Sanchez, Tercedor L., Van de Heyning, C. M., Vial, H., Vlieghe, E., Vonkeman, H. E., Vreugdenhil, P., de Vries, T. A. C., Willems, A. M., Wils, A. M., Zoet-Nugteren, S. K., Linschoten, M., Uijl, A., Schut, A., Jakob, C. E. M., Romao, L. R., Bell, R. M., McFarlane, E., Stecher, M., Zondag, A. G. M., van Iperen, E. P. A., Hermans-van Ast, J. F., Lea, N. C., Schaap, J., Jewbali, L. S., Smits, P. C., Patel, R. S., Aujayeb, A., van Smeden, M., Siebelink, H. J., Williams, S., Pilgram, L., Tieleman, R. G., Williams, B., Asselbergs, F. W., Al-Ali, A. K., Al-Muhanna, F. A., Al-Rubaish, A. M., Al-Windy, N. Y. Y., Alkhalil, M., Almubarak, Y. A., Al Nafie, A. N., Al Shahrani, M., Al Shehri, A. M., Anning, C., Anthonio, R. L., Badings, E. A., Ball, C., Van Beek, E. A., Ten Berg, J. M., Von Bergwelt-Baildon, M., Bianco, M., Blagova, O., V, Bleijendaal, H., Bor, W. L., Borgmann, S., van Boxem, A. J. M., van den Brink, F. S., Bucciarelli-Ducci, C., Van Bussel, B. C. T., Byrom-Goulthorp, R., Captur, G., Caputo, M., Charlotte, N., vom Dahl, J., Dark, P., De Sutter, J., Degenhardt, C., Delsing, C. E., Dolff, S., Dorman, H. G. R., Drost, J. T., Eberwein, L., Emans, M. E., Er, A. G., Ferreira, J. B., Forner, M. J., Friedrichs, A., Gabriel, L., Groenemeijer, B. E., Groenendijk, A. L., Gruener, B., Guggemos, W., Haerkens-Arends, H. E., Hanses, F., Hedayat, B., Heigener, D., van der Heijden, D. J., Hellou, E., Hellwig, K., Henkens, M. T. H. M., Hermanides, R. S., Hermans, W. R. M., van Hessen, M. W. J., Heymans, S. R. B., Hilt, A. D., van der Horst, I. C. C., Hower, M., van Ierssel, S. H., Isberner, N., Jensen, B., Kearney, M. T., Kielstein, J. T., Kietselaer, B. L. J. H., Kochanek, M., Kolk, M. Z. H., Koning, A. M. H., Kopylov, P. Y., Kuijper, A. F. M., Kwakkel-van, E. R. P. J. M., Lanznaster, J., van der Linden, M. M. J. M., van der Lingen, A. C. J., Linssen, G. C. M., Lomas, D., Maarse, M., Magdelijns, F. J. H., Magro, M., Markart, P., Martens, F. M. A. C., Mazzilli, S. G., McCann, G. P., van der Meer, P., Meijs, M. F. L., Merle, U., Messiaen, P., Milovanovic, M., Monraats, P. S., Montagna, L., Moriarty, A., Moss, A. J., Mosterd, A., Nadalin, S., Nattermann, J., Neufang, M., Nierop, P. R., Offerhaus, J. A., Van Ofwegen-Hanekamp, C. E. E., Parker, E., Persoon, A. M., Piepel, C., Pinto, Y. M., Poorhosseini, H., Prasad, S., Raafs, A. G., Raichle, C., Rauschning, D., Redon, J., Reidinga, A. C., Ribeiro, M. I. A., Riedel, C., Rieg, S., Ripley, D. P., Rommele, C., Rothfuss, K., Ruddel, J., Ruthrich, M. M., Salah, R., Saneei, E., Saxena, M., Schellings, D. A. A. M., Scholte, N. T. B., Schubert, J., Seelig, J., Shafiee, A., Shore, A. C., Spinner, C., Stieglitz, S., Strauss, R., Sturkenboom, N. H., Tessitore, E., Thomson, R. J., Timmermans, P. J. R., Tio, R. A., Tjong, F. V. Y., Tometten, L., Trauth, J., Van Craenenbroeck, E. M., van Veen, H. P. A. A., den Uil, C. A., Vehreschild, M. J. G. T., Veldhuis, L., I, Veneman, T., Verschure, D. O., Voigt, I, Walter, L., vande Watering, D. J., de Vries, J. K., vande Wal, R. M. A., Westendorp, I. C. D., Westendorp, P. H. M., Westhoff, T., Weytjens, C., Wierda, E., Wille, K., de With, K., Worm, M., Woudstra, P., Wu, K. W., Zaal, R., Zaman, A. G., van der Zee, P. M., Zijlstra, L. E., Alling, T. E., Ahmed, R., Bayraktar-Verver, E. C. E., van Aken, K., Jimenes, Bermudez F. J., Biole, C. A., Den Boer-Penning, P., Bontje, M., Bos, M., Bosch, L., Broekman, M., Broeyer, F. J. F., de Bruijn, E. A. W., Bruinsma, S., Cardoso, N. M., Cosyns, B., Len, van Da D. H., Dekimpe, E., Domange, J., van Doorn, J. L., van DOorn, P., Dormal, F., Drost, I. M. J., Dunnink, A., van Eck, J. W. M., Elshinawy, K., Gevers, R. M. M., Gognieva, D. G., van der Graaf, M., Grangeon, S., Guclu, A., Habib, A., Haenen, N. A., Hamilton, K., Handgraaf, S., Heidbuchel, H., Hendriks-van Woerden, M., Hessels-Linnemeijer, B. M., Hosseini, K., Huisman, J., Jacobs, T. C., Jansen, S. E., Janssen, A., Jourdan, K., ten Kate, G. L., van Kempen, M. J., Kievit, C. M., Kleikers, P., Knufman, N., van der Kooi, S. E., Koole, B. A. S., Koole, M. A. C., Kui, K. K., Kuipers-Elferink, L., Lemoine, I, Lensink, E., van Marrewijk, V, Meijer, E. J., Melein, A. J., Mesitskaya, D. F., van Nes, C. P. M., Paris, F. M. A., Perrelli, M. G., Pieterse-Rots, A., Pisters, R., Polkerman, B. C., van Poppel, A., Reinders, S., Reitsma, M. J., Ruiter, A. H., Selder, J. L., van der Sluis, A., Sousa, A. I. C., Tajdini, M., Sanchez, Tercedor L., Van de Heyning, C. M., Vial, H., Vlieghe, E., Vonkeman, H. E., Vreugdenhil, P., de Vries, T. A. C., Willems, A. M., Wils, A. M., and Zoet-Nugteren, S. K.

Abstract

Aims Patients with cardiac disease are considered high risk for poor outcomes following hospitalization with COVID-19. The primary aim of this study was to evaluate heterogeneity in associations between various heart disease subtypes and in-hospital mortality. Methods and results We used data from the CAPACITY-COVID registry and LEOSS study. Multivariable Poisson regression models were fitted to assess the association between different types of pre-existing heart disease and in-hospital mortality. A total of 16 511 patients with COVID-19 were included (21.1% aged 66-75 years; 40.2% female) and 31.5% had a history of heart disease. Patients with heart disease were older, predominantly male, and often had other comorbid conditions when compared with those without. Mortality was higher in patients with cardiac disease (29.7%; n= 1545 vs. 15.9%; n= 1797). However, following multivariable adjustment, this difference was not significant [adjusted risk ratio (aRR) 1.08, 95% confidence interval (CI) 1.02-1.15; P = 0.12 (corrected for multiple testing)]. Associations with in-hospital mortality by heart disease subtypes differed considerably, with the strongest association for heart failure (aRR 1.19, 95% CI 1.10-1.30; P <0.018) particularly for severe (New York Heart Association class III/IV) heart failure (aRR 1.41, 95% CI 1.20-1.64; P < 0.018). None of the other heart disease subtypes, including ischaemic heart disease, remained significant after multivariable adjustment. Serious cardiac complications were diagnosed in <1% of patients. Conclusion Considerable heterogeneity exists in the strength of association between heart disease subtypes and in-hospital mortality. Of all patients with heart disease, those with heart failure are at greatest risk of death when hospitalized with COVID-19. Serious cardiac complications are rare during hospitalization. [GRAPHICS] .

Published
2022

26. S3 Guideline: Diagnosis and Therapy of Biliary Carcinoma Short Version 2.00-June 2021, AWMF Register Number: 032-053OL

Author

Bitzer, M., Voesch, S., Albert, J., Bartenstein, P., Bechstein, W., Bloedt, S., Brunner, T., Dombrowski, F., Evert, M., Follmann, M., La Fougere, C., Freudenberger, P., Geier, A., Gkika, E., Goetz, M., Hammes, E., Helmberger, T., Hoffmann, R. T., Hofmann, W. P., Huppert, P., Kautz, A., Knoetgen, G., Koerber, J., Krug, D., Lammert, F., Lang, H., Langer, T., Lenz, P., Mahnken, A., Meining, A., Micke, O., Nadalin, S., Nguyen, H. P., Ockenga, J., Oldhafer, K., Paprottka, P., Paradies, K., Pereira, P., Persigehl, T., Plauth, M., Plentz, R., Pohl, J., Riemer, J., Reimer, P., Ringwald, J., Ritterbusch, U., Roeb, E., Schellhaas, B., Schirmacher, P., Schmid, I, Schuler, A., von Schweinitz, D., Seehofer, D., Sinn, M., Stein, A., Stengel, A., Steubesand, N., Stoll, C., Tannapfel, A., Taubert, A., Trojan, J., van Thiel, I, Tholen, R., Vogel, A., Vogl, T., Vorwerk, H., Wacker, F., Waidmann, O., Wedemeyer, H., Wege, H., Wildner, D., Wittekind, C., Woerns, M. A., Galle, P., Malek, N., Bitzer, M., Voesch, S., Albert, J., Bartenstein, P., Bechstein, W., Bloedt, S., Brunner, T., Dombrowski, F., Evert, M., Follmann, M., La Fougere, C., Freudenberger, P., Geier, A., Gkika, E., Goetz, M., Hammes, E., Helmberger, T., Hoffmann, R. T., Hofmann, W. P., Huppert, P., Kautz, A., Knoetgen, G., Koerber, J., Krug, D., Lammert, F., Lang, H., Langer, T., Lenz, P., Mahnken, A., Meining, A., Micke, O., Nadalin, S., Nguyen, H. P., Ockenga, J., Oldhafer, K., Paprottka, P., Paradies, K., Pereira, P., Persigehl, T., Plauth, M., Plentz, R., Pohl, J., Riemer, J., Reimer, P., Ringwald, J., Ritterbusch, U., Roeb, E., Schellhaas, B., Schirmacher, P., Schmid, I, Schuler, A., von Schweinitz, D., Seehofer, D., Sinn, M., Stein, A., Stengel, A., Steubesand, N., Stoll, C., Tannapfel, A., Taubert, A., Trojan, J., van Thiel, I, Tholen, R., Vogel, A., Vogl, T., Vorwerk, H., Wacker, F., Waidmann, O., Wedemeyer, H., Wege, H., Wildner, D., Wittekind, C., Woerns, M. A., Galle, P., and Malek, N.

Published
2022

27. S3-Guideline - Diagnosis and Therapy of Biliary Carcinoma

Author

Bitzer, M., Voesch, S., Albert, J., Bartenstein, P., Bechstein, W., Bloedt, S., Brunner, T., Dombrowski, F., Evert, M., Follmann, M., La Fougere, C., Freudenberger, P., Geier, A., Gkika, E., Goetz, M., Hammes, E., Helmberger, T., Hoffmann, R. T., Hofmann, W. P., Huppert, P., Kautz, A., Knoetgen, G., Koerber, J., Krug, D., Lammert, F., Lang, H., Langer, T., Lenz, P., Mahnken, A., Meining, A., Micke, O., Nadalin, S., Nguyen, H. P., Ockenga, J., Oldhafer, K., Paprottka, P., Paradies, K., Pereira, P., Persigehl, T., Plauth, M., Plentz, R., Pohl, J., Riemer, J., Reimer, P., Ringwald, J., Ritterbusch, U., Roeb, E., Schellhaas, B., Schirmacher, P., Schmid, I, Schuler, A., von Schweinitz, D., Seehofer, D., Sinn, M., Stein, A., Stengel, A., Steubesand, N., Stoll, C., Tannapfel, A., Taubert, A., Trojan, J., van Thiel, I, Tholen, R., Vogel, A., Vogl, T., Vorwerk, H., Wacker, F., Waidmann, O., Wedemeyer, H., Wege, H., Wildner, D., Wittekind, C., Woerns, M. A., Galle, P., Malek, N., Bitzer, M., Voesch, S., Albert, J., Bartenstein, P., Bechstein, W., Bloedt, S., Brunner, T., Dombrowski, F., Evert, M., Follmann, M., La Fougere, C., Freudenberger, P., Geier, A., Gkika, E., Goetz, M., Hammes, E., Helmberger, T., Hoffmann, R. T., Hofmann, W. P., Huppert, P., Kautz, A., Knoetgen, G., Koerber, J., Krug, D., Lammert, F., Lang, H., Langer, T., Lenz, P., Mahnken, A., Meining, A., Micke, O., Nadalin, S., Nguyen, H. P., Ockenga, J., Oldhafer, K., Paprottka, P., Paradies, K., Pereira, P., Persigehl, T., Plauth, M., Plentz, R., Pohl, J., Riemer, J., Reimer, P., Ringwald, J., Ritterbusch, U., Roeb, E., Schellhaas, B., Schirmacher, P., Schmid, I, Schuler, A., von Schweinitz, D., Seehofer, D., Sinn, M., Stein, A., Stengel, A., Steubesand, N., Stoll, C., Tannapfel, A., Taubert, A., Trojan, J., van Thiel, I, Tholen, R., Vogel, A., Vogl, T., Vorwerk, H., Wacker, F., Waidmann, O., Wedemeyer, H., Wege, H., Wildner, D., Wittekind, C., Woerns, M. A., Galle, P., and Malek, N.

Published
2022

28. Location and allocation: inequity of access to liver transplantation for patients with severe acute‐on‐chronic liver failure in Europe

Author

Artzner, T, Bernal, W, Belli, L, Conti, S, Cortesi, P, Sacleux, S, Pageaux, G, Radenne, S, Trebicka, J, Fernandez, J, Perricone, G, Piano, S, Nadalin, S, Morelli, M, Martini, S, Polak, W, Zieniewicz, K, Toso, C, Berenguer, M, Iegri, C, Invernizzi, F, Volpes, R, Karam, V, Adam, R, Faitot, F, Rabinowich, L, Saliba, F, Meunier, L, Lesurtel, M, Uschner, F, Michard, B, Coilly, A, Meszaros, M, Poinsot, D, Besch, C, Schnitzbauer, A, De Carlis, L, Fumagalli, R, Angeli, P, Arroyo, V, Fondevila, C, Duvoux, C, Jalan, R, Viganò, R, Mazzarelli, C, Lauterio, A, Giacomoni, A, Donato, F, Lampertico, P, Pasulo, L, Fagiuoli, S, Colledan, M, Cristina Morelli, M, Vitale, G, Ottobrelli, A, Patrono, D, Romagnoli, R, Petridis, I, Cillo, U, Germani, G, Burra, P, Bachellier, P, Schneider, F, Castelain, V, Addeo, P, Deridder, M, Caroline Sacleux Audrey Coilly, S, Faouzi, S, Samuel, D, Guichon, C, Faure, S, Ursic‐bedoya, J, Colmenero, J, Toapanta, D, Hernández‐tejero, M, Vinaixa, C, den Hoed, C, Haan, J, Della Penna, A, Erhard Uschner, F, Welker, M, Zeuzem, S, Bechstein, W, Goossens, N, Raszeja‐wyszomirska, J, Rabinovich, L, Katarey, D, Agarwal, B, Artzner, Thierry, Bernal, William, Belli, Luca S, Conti, Sara, Cortesi, Paolo A, Sacleux, Sophie‐Caroline, Pageaux, George‐Philippe, Radenne, Sylvie, Trebicka, Jonel, Fernandez, Javier, Perricone, Giovanni, Piano, Salvatore, Nadalin, Silvio, Morelli, Maria C, Martini, Silvia, Polak, Wojciech G, Zieniewicz, Krzysztof, Toso, Christian, Berenguer, Marina, Iegri, Claudia, Invernizzi, Federica, Volpes, Riccardo, Karam, Vincent, Adam, René, Faitot, François, Rabinowich, Liane, Saliba, Faouzi, Meunier, Lucy, Lesurtel, Mickael, Uschner, Frank E, Michard, Baptiste, Coilly, Audrey, Meszaros, Magdalena, Poinsot, Domitille, Besch, Camille, Schnitzbauer, Andreas, De Carlis, Luciano G, Fumagalli, Roberto, Angeli, Paolo, Arroyo, Vincente, Fondevila, Constantino, Duvoux, Christophe, Jalan, Rajiv, Viganò, Raffaella, Mazzarelli, Chiara, Lauterio, Andrea, Giacomoni, Alessandro, Donato, Francesca, Lampertico, Pietro, Pasulo, Luisa, Fagiuoli, Stefano, Colledan, Michele, Cristina Morelli, Maria, Vitale, Giovanni, Ottobrelli, Antonio, Patrono, Damiano, Romagnoli, Renato, Petridis, Ioannis, Cillo, Umberto, Germani, Giacomo, Burra, Patrizia, Bachellier, Philippe, Schneider, Francis, Castelain, Vincent, Addeo, Pietro, Deridder, Mathilde, Caroline Sacleux Audrey Coilly, Sophie, Faouzi, Saliba, Adam, Rene, Samuel, Didier, Guichon, Celine, Faure, Stéfanie, Ursic‐Bedoya, Josè, Fondevila, Costantino, Colmenero, Jorde, Toapanta, David, Hernández‐Tejero, María, Vinaixa, Carmen, Polak, Wojciech G., den Hoed, Caroline, Haan, Jubi E., Della Penna, Andrea, Erhard Uschner, Frank, Welker, Martin, Zeuzem, Stefan, Bechstein, Wolf, Goossens, Nicolas, Raszeja‐Wyszomirska, Joanna, Rabinovich, Liane, Katarey, Dev, Agarwal, Banwari, Artzner, T, Bernal, W, Belli, L, Conti, S, Cortesi, P, Sacleux, S, Pageaux, G, Radenne, S, Trebicka, J, Fernandez, J, Perricone, G, Piano, S, Nadalin, S, Morelli, M, Martini, S, Polak, W, Zieniewicz, K, Toso, C, Berenguer, M, Iegri, C, Invernizzi, F, Volpes, R, Karam, V, Adam, R, Faitot, F, Rabinowich, L, Saliba, F, Meunier, L, Lesurtel, M, Uschner, F, Michard, B, Coilly, A, Meszaros, M, Poinsot, D, Besch, C, Schnitzbauer, A, De Carlis, L, Fumagalli, R, Angeli, P, Arroyo, V, Fondevila, C, Duvoux, C, Jalan, R, Viganò, R, Mazzarelli, C, Lauterio, A, Giacomoni, A, Donato, F, Lampertico, P, Pasulo, L, Fagiuoli, S, Colledan, M, Cristina Morelli, M, Vitale, G, Ottobrelli, A, Patrono, D, Romagnoli, R, Petridis, I, Cillo, U, Germani, G, Burra, P, Bachellier, P, Schneider, F, Castelain, V, Addeo, P, Deridder, M, Caroline Sacleux Audrey Coilly, S, Faouzi, S, Samuel, D, Guichon, C, Faure, S, Ursic‐bedoya, J, Colmenero, J, Toapanta, D, Hernández‐tejero, M, Vinaixa, C, den Hoed, C, Haan, J, Della Penna, A, Erhard Uschner, F, Welker, M, Zeuzem, S, Bechstein, W, Goossens, N, Raszeja‐wyszomirska, J, Rabinovich, L, Katarey, D, Agarwal, B, Artzner, Thierry, Bernal, William, Belli, Luca S, Conti, Sara, Cortesi, Paolo A, Sacleux, Sophie‐Caroline, Pageaux, George‐Philippe, Radenne, Sylvie, Trebicka, Jonel, Fernandez, Javier, Perricone, Giovanni, Piano, Salvatore, Nadalin, Silvio, Morelli, Maria C, Martini, Silvia, Polak, Wojciech G, Zieniewicz, Krzysztof, Toso, Christian, Berenguer, Marina, Iegri, Claudia, Invernizzi, Federica, Volpes, Riccardo, Karam, Vincent, Adam, René, Faitot, François, Rabinowich, Liane, Saliba, Faouzi, Meunier, Lucy, Lesurtel, Mickael, Uschner, Frank E, Michard, Baptiste, Coilly, Audrey, Meszaros, Magdalena, Poinsot, Domitille, Besch, Camille, Schnitzbauer, Andreas, De Carlis, Luciano G, Fumagalli, Roberto, Angeli, Paolo, Arroyo, Vincente, Fondevila, Constantino, Duvoux, Christophe, Jalan, Rajiv, Viganò, Raffaella, Mazzarelli, Chiara, Lauterio, Andrea, Giacomoni, Alessandro, Donato, Francesca, Lampertico, Pietro, Pasulo, Luisa, Fagiuoli, Stefano, Colledan, Michele, Cristina Morelli, Maria, Vitale, Giovanni, Ottobrelli, Antonio, Patrono, Damiano, Romagnoli, Renato, Petridis, Ioannis, Cillo, Umberto, Germani, Giacomo, Burra, Patrizia, Bachellier, Philippe, Schneider, Francis, Castelain, Vincent, Addeo, Pietro, Deridder, Mathilde, Caroline Sacleux Audrey Coilly, Sophie, Faouzi, Saliba, Adam, Rene, Samuel, Didier, Guichon, Celine, Faure, Stéfanie, Ursic‐Bedoya, Josè, Fondevila, Costantino, Colmenero, Jorde, Toapanta, David, Hernández‐Tejero, María, Vinaixa, Carmen, Polak, Wojciech G., den Hoed, Caroline, Haan, Jubi E., Della Penna, Andrea, Erhard Uschner, Frank, Welker, Martin, Zeuzem, Stefan, Bechstein, Wolf, Goossens, Nicolas, Raszeja‐Wyszomirska, Joanna, Rabinovich, Liane, Katarey, Dev, and Agarwal, Banwari

Abstract

Background: There is growing evidence that liver transplantation (LT) is the most effective treatment for acute-on-chronic liver failure grade-3 (ACLF-3). This study examines whether and how this evidence translates into practice by analyzing the variability in intensive care unit (ICU) admissions, listing strategies and LT activity for ACLF-3 patients across transplant centers in Europe. Methods: Consecutive patients who were admitted to the ICU with ACLF-3, whether or not they were listed and/or transplanted with ACLF-3 between 2018 and 2019 were included across 20 transplantation centers. Results: 351 patients with ACLF-3 were included: 33 had been listed prior to developing ACLF-3 and 318 had not been listed at the time of admission to the ICU. There was no correlation between the number of unlisted ACLF-3 patients admitted to the ICU and the number listed or transplanted whilst in ACLF-3 across centers. In contrast, there was a correlation between the number of patients listed and the number transplanted whilst in ACLF-3. 21% of patients who were listed whilst in ACLF-3 died on the waiting list or were delisted. The percentage of LT for ACLF-3 patients varied from 0%-29% of patients transplanted with decompensated cirrhosis across centers (average = 8%), with an I2 index of 68% (95% CI: 49%-80%), showing substantial heterogeneity among centers. The one-year survival for all patients with ACLF-3 was significantly higher in centers that listed and transplanted more ACLF-3 patients (>10 patients) than in centers that listed and transplanted fewer: respectively 36% vs. 20%, p = 0.012. Conclusion: Patients with ACLF-3 face inequity of access to LT across Europe. Wait-listing strategies for ACLF-3 patients influence their access to LT and, ultimately, their survival.

Published
2022

29. European Liver Transplant Registry: Donor and transplant surgery aspects of 16,641 liver transplantations in children

Author

de Ville de Goyet, J, Baumann, U, Karam, V, Adam, R, Nadalin, S, Heaton, N, Reding, R, Branchereau, S, Mirza, D, Klempnauer, J, Fischer, L, Kalicinski, P, Colledan, M, Lopez Santamaria, M, de Kleine, R, Chardot, C, Yilmaz, S, Kilic, M, Boillot, O, di Francesco, F, Polak, W, Verkade, H, de Ville de Goyet, Jean, Baumann, Ulrich, Karam, Vincent, Adam, René, Nadalin, Silvio, Heaton, Nigel, Reding, Raymond, Branchereau, Sophie, Mirza, Darius, Klempnauer, Jürgen L, Fischer, Lutz, Kalicinski, Piotr, Colledan, Michele, Lopez Santamaria, Manuel, de Kleine, Ruben H, Chardot, Christophe, Yilmaz, Sezai, Kilic, Murat, Boillot, Olivier, di Francesco, Fabrizio, Polak, Wojciech G, Verkade, Henkjan J, de Ville de Goyet, J, Baumann, U, Karam, V, Adam, R, Nadalin, S, Heaton, N, Reding, R, Branchereau, S, Mirza, D, Klempnauer, J, Fischer, L, Kalicinski, P, Colledan, M, Lopez Santamaria, M, de Kleine, R, Chardot, C, Yilmaz, S, Kilic, M, Boillot, O, di Francesco, F, Polak, W, Verkade, H, de Ville de Goyet, Jean, Baumann, Ulrich, Karam, Vincent, Adam, René, Nadalin, Silvio, Heaton, Nigel, Reding, Raymond, Branchereau, Sophie, Mirza, Darius, Klempnauer, Jürgen L, Fischer, Lutz, Kalicinski, Piotr, Colledan, Michele, Lopez Santamaria, Manuel, de Kleine, Ruben H, Chardot, Christophe, Yilmaz, Sezai, Kilic, Murat, Boillot, Olivier, di Francesco, Fabrizio, Polak, Wojciech G, and Verkade, Henkjan J

Abstract

Background and Aims: The European Liver Transplant Registry (ELTR) has collected data on liver transplant procedures performed in Europe since 1968. Approach and Results: Over a 50-year period (1968–2017), clinical and laboratory data were collected from 133 transplant centers and analyzed retrospectively (16,641 liver transplants in 14,515 children). Data were analyzed according to three successive periods (A, before 2000; B, 2000–2009; and C, since 2010), studying donor and graft characteristics and graft outcome. The use of living donors steadily increased from A to C (A, n = 296 [7%]; B, n = 1131 [23%]; and C, n = 1985 [39%]; p = 0.0001). Overall, the 5-year graft survival rate has improved from 65% in group A to 75% in group B (p < 0.0001) and to 79% in group C (B versus C, p < 0.0001). Graft half-life was 31 years, overall; it was 41 years for children who survived the first year after transplant. The late annual graft loss rate in teenagers is higher than that in children aged <12 years and similar to that of young adults. No evidence for accelerated graft loss after age 18 years was found. Conclusions: Pediatric liver transplantation has reached a high efficacy as a cure or treatment for severe liver disease in infants and children. Grafts that survived the first year had a half-life similar to standard human half-life. Transplantation before or after puberty may be the pivot-point for lower long-term outcome in children. Further studies are necessary to revisit some old concepts regarding transplant benefit (survival time) for small children, the role of recipient pathophysiology versus graft aging, and risk at transition to adult age.

Published
2022

33. A Randomized, Controlled Study to Assess the Conversion From Calcineurin-Inhibitors to Everolimus After Liver Transplantation—PROTECT

Author

Fischer, L., Klempnauer, J., Beckebaum, S., Metselaar, H.J., Neuhaus, P., Schemmer, P., Settmacher, U., Heyne, N., Clavien, P-A., Muehlbacher, F., Morard, I., Wolters, H., Vogel, W., Becker, T., Sterneck, M., Lehner, F., Klein, C., Kazemier, G., Pascher, A., Schmidt, J., Rauchfuss, F., Schnitzbauer, A., Nadalin, S., Hack, M., Ladenburger, S., and Schlitt, H.J.

Published
2012
Full Text
View/download PDF

34. S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome

Author

Bitzer, M., Voesch, S., Albert, J., Bartenstein, P., Bechstein, W., Blödt, S., Brunner, T., Dombrowski, F., Evert, M., Follmann, M., La Fougère, C., Freudenberger, P., Geier, A., Gkika, E., Götz, M., Hammes, E., Helmberger, T., Hoffmann, R.T., Hofmann, W.P., Huppert, P., Kautz, A., Knötgen, G., Körber, J., Krug, D., Lammert, F., Lang, H., Langer, T., Lenz, P., Mahnken, A., Meining, A., Micke, O., Nadalin, S., Nguyen, H.P., Ockenga, J., Oldhafer, K., Paprottka, P., Paradies, K., Pereira, P., Persigehl, T., Plauth, M., Plentz, R., Pohl, J., Riemer, J., Reimer, P., Ringwald, J., Ritterbusch, Ulrike, Roeb, E., Schellhaas, B., Schirmacher, P., Schmid, I., Schuler, A., von Schweinitz, D., Seehofer, D., Sinn, M., Stein, A., Stengel, A., Steubesand, N., Stoll, C., Tannapfel, A., Taubert, A., Trojan, J., van Thiel, I., Tholen, R., Vogel, A., Vogl, T., Vorwerk, H., Wacker, F., Waidmann, O., Wedemeyer, H., Wege, H., Wildner, D., Wittekind, C., Wörns, M.A., Galle, P., and Malek, N.

Subjects
Medizin
Published
2022

35. Hepatocellular carcinoma progression during bridging before liver transplantation

Author

Renner P., Da Silva T., Schnitzbauer A. A., Verloh N., Schlitt H. J., Geissler E. K., Zulke C., Lamby P. E., Proneth A., Duvoux C., Burra P., Jauch K. -W., Rentsch M., Ganten T. M., Schmidt J., Settmacher U., Heise M., Rossi G., Cillo U., Kneteman N., Adam R., Van Hoek B., Bachellier P., Wolf P., Rostaing L., Bechstein W. O., Rizell M., Powell J., Hidalgo E., Gugenheim J., Wolters H., Brockmann J., Roy A., Mutzbauer I., Schlitt A., Beckebaum S., Graeb C., Nadalin S., Valente U., Sanchez Turrion V., Jamieson N., Scholz T., Colledan M., Fandrich F., Becker T., Soderdahl G., Chazouilleres O., Makisalo H., Pageaux G. -P., Steininger R., Soliman T., De Jong K. P., Pirenne J., Margreiter R., Pratschke J., Pinna A. D., Hauss J., Schreiber S., Strasser S., Klempnauer J., Troisi R. I., Bhoori S., Lerut J., Bilbao I., Klein C. G., Konigsrainer A., Otto G., Mazzaferro V., Neuhaus P., Renner, P, Da Silva, T, Schnitzbauer, A, Verloh, N, Schlitt, H, Geissler, E, Zulke, C, Lamby, P, Proneth, A, Duvoux, C, Burra, P, Jauch, K, Rentsch, M, Ganten, T, Schmidt, J, Settmacher, U, Heise, M, Rossi, G, Cillo, U, Kneteman, N, Adam, R, Van Hoek, B, Bachellier, P, Wolf, P, Rostaing, L, Bechstein, W, Rizell, M, Powell, J, Hidalgo, E, Gugenheim, J, Wolters, H, Brockmann, J, Roy, A, Mutzbauer, I, Schlitt, A, Beckebaum, S, Graeb, C, Nadalin, S, Valente, U, Sanchez Turrion, V, Jamieson, N, Scholz, T, Colledan, M, Fandrich, F, Becker, T, Soderdahl, G, Chazouilleres, O, Makisalo, H, Pageaux, G, Steininger, R, Soliman, T, De Jong, K, Pirenne, J, Margreiter, R, Pratschke, J, Pinna, A, Hauss, J, Schreiber, S, Strasser, S, Klempnauer, J, Troisi, R, Bhoori, S, Lerut, J, Bilbao, I, Klein, C, Konigsrainer, A, Otto, G, Mazzaferro, V, Neuhaus, P, and Publica

Subjects
Male, Carcinoma, Hepatocellular, Time Factor, Waiting Lists, AcademicSubjects/MED00910, Prognosi, Risk Factor, Middle Aged, Liver Transplantation, Treatment Outcome, Liver Neoplasm, Disease Progression, Female, Original Article, Survival Analysi, Neoplasm Recurrence, Local, AcademicSubjects/MED00010, Multivariate Analysi, Human
Abstract

Background Recipient selection for liver transplantation in hepatocellular carcinoma (HCC) is based primarily on criteria affecting the chance of long-term success. Here, the relationship between pretransplant bridging therapy and long-term survival was investigated in a subgroup analysis of the SiLVER Study. Methods Response to bridging, as defined by comparison of imaging at the time of listing and post-transplant pathology report, was categorized into controlled versus progressive disease (more than 20 per cent tumour growth or development of new lesions). Results Of 525 patients with HCC who had liver transplantation, 350 recipients underwent pretransplant bridging therapy. Tumour progression despite bridging was an independent risk factor affecting overall survival (hazard ratio 1.80; P = 0.005). For patients within the Milan criteria (MC) at listing, mean overall survival was longer for those with controlled versus progressive disease (6.8 versus 5.8 years; P

Published
2021

40. S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome

Author

Bitzer, M., additional, Voesch, S., additional, Albert, J., additional, Bartenstein, P., additional, Bechstein, W., additional, Blödt, S., additional, Brunner, T., additional, Dombrowski, F., additional, Evert, M., additional, Follmann, M., additional, La Fougère, C., additional, Freudenberger, P., additional, Geier, A., additional, Gkika, E., additional, Götz, M., additional, Hammes, E., additional, Helmberger, T., additional, Hoffmann, R. T., additional, Hofmann, W. P., additional, Huppert, P., additional, Kautz, A., additional, Knötgen, G., additional, Körber, J., additional, Krug, D., additional, Lammert, F., additional, Lang, H., additional, Langer, T., additional, Lenz, P., additional, Mahnken, A., additional, Meining, A., additional, Micke, O., additional, Nadalin, S., additional, Nguyen, H. P., additional, Ockenga, J., additional, Oldhafer, K., additional, Paprottka, P., additional, Paradies, K., additional, Pereira, P., additional, Persigehl, T., additional, Plauth, M., additional, Plentz, R., additional, Pohl, J., additional, Riemer, J., additional, Reimer, P., additional, Ringwald, J., additional, Ritterbusch, U., additional, Roeb, E., additional, Schellhaas, B., additional, Schirmacher, P., additional, Schmid, I., additional, Schuler, A., additional, von Schweinitz, D., additional, Seehofer, D., additional, Sinn, M., additional, Stein, A., additional, Stengel, A., additional, Steubesand, N., additional, Stoll, C., additional, Tannapfel, A., additional, Taubert, A., additional, Trojan, J., additional, van Thiel, I., additional, Tholen, R., additional, Vogel, A., additional, Vogl, T., additional, Vorwerk, H., additional, Wacker, F., additional, Waidmann, O., additional, Wedemeyer, H., additional, Wege, H., additional, Wildner, D., additional, Wittekind, C., additional, Wörns, M. A., additional, Galle, P., additional, and Malek, N., additional

Published
2022
Full Text
View/download PDF

43. Successful long-term management of recurrent focal segmental glomerulosclerosis after kidney transplantation with costimulation blockade

Author

Mühlbacher, T., Amann, K., Mahling, M., Nadalin, S., Heyne, N., and Guthoff, M.

Subjects
focal segmental glomerulosclerosis, B7-1, recurrence, nephrotic syndrome, kidney transplantation, Exceptional Cases, Belatacept, Focal Segmental Glomerulosclerosis, Kidney Transplantation, Nephrotic Syndrome, Recurrence, AcademicSubjects/MED00340, belatacept
Abstract

Recurrence of primary focal segmental glomerulosclerosis (FSGS) occurs in up to 50% of patients after kidney transplantation and is associated with poor allograft outcome. Novel therapeutic concepts directly target podocyte function via B7-1 with inconsistent response. We present the case of a 19-year-old patient with recurrent primary FSGS early after living donor kidney transplantation. Plasmapheresis and rituximab did not induce remission. Repetitive abatacept administration was able to achieve partial remission. Maintenance immunosuppression was subsequently switched to a belatacept-based calcineurin inhibitor-free immunosuppression, resulting in sustained complete remission with excellent allograft function throughout a follow-up of >56 months.

Published
2020

45. Correction to: Portal Vein Embolization is Associated with Reduced Liver Failure and Mortality in High-Risk Resections for Perihilar Cholangiocarcinoma (Annals of Surgical Oncology, (2020), 10.1245/s10434-020-08258-3)

Author

Olthof P. B., Aldrighetti L., Alikhanov R., Cescon M., Groot Koerkamp B., Jarnagin W. R., Nadalin S., Pratschke J., Schmelzle M., Sparrelid E., Lang H., Guglielmi A., van Gulik T. M., Andreou A., Bartsch F., Benzing C., Buettner S., Capobianco I., de Reuver P., de Savornin Lohman E., Dejong C. H. C., Efanov M., Erdmann J. I., Franken L. C., Frascaroli G., Giglio M. C., Gomez-Gavara C., Heid F., IJzermans J. N. M., Jansson H., Ligthart M. A. P., Maithel S. K., Malago M., Malik H. Z., Muiesan P., Olde Damink S. W. M., Pando E., Quinn L. M., Ratti F., Roberts K. J., Rolinger J., Ruzzenente A., Schadde E., Serenari M., Sultana A., Troisi R., van Laarhoven S., van Vugt J. L. A., Olthof, P. B., Aldrighetti, L., Alikhanov, R., Cescon, M., Groot Koerkamp, B., Jarnagin, W. R., Nadalin, S., Pratschke, J., Schmelzle, M., Sparrelid, E., Lang, H., Guglielmi, A., van Gulik, T. M., Andreou, A., Bartsch, F., Benzing, C., Buettner, S., Capobianco, I., de Reuver, P., de Savornin Lohman, E., Dejong, C. H. C., Efanov, M., Erdmann, J. I., Franken, L. C., Frascaroli, G., Giglio, M. C., Gomez-Gavara, C., Heid, F., Ijzermans, J. N. M., Jansson, H., Ligthart, M. A. P., Maithel, S. K., Malago, M., Malik, H. Z., Muiesan, P., Olde Damink, S. W. M., Pando, E., Quinn, L. M., Ratti, F., Roberts, K. J., Rolinger, J., Ruzzenente, A., Schadde, E., Serenari, M., Sultana, A., Troisi, R., van Laarhoven, S., and van Vugt, J. L. A.

Abstract

In the original article Moritz Schmelzle’s last name is spelled wrong. It is correct as reflected here.

Published
2020

46. Portal Vein Embolization is Associated with Reduced Liver Failure and Mortality in High-Risk Resections for Perihilar Cholangiocarcinoma

Author

Olthof, P. B., Aldrighetti, L., Alikhanov, R., Cescon, M., Groot Koerkamp, B., Jarnagin, W. R., Nadalin, S., Pratschke, J., Schmelze, M., Sparrelid, E., Lang, H., Guglielmi, A., van Gulik, T. M., Andreou, A., Bartsch, F., Benzing, C., Buettner, S., Capobianco, I., de Reuver, P., de Savornin Lohman, E., Dejong, C. H. C., Efanov, M., Erdmann, J. I., Franken, L. C., Frascaroli, G., Giglio, M. C., Gomez-Gavara, C., Heid, F., IJzermans, J. N. M., Jansson, H., Ligthart, M. A. P., Maithel, S. K., Malago, M., Malik, H. Z., Muiesan, P., Olde Damink, S. W. M., Pando, E., Quinn, L. M., Ratti, F., Roberts, K. J., Rolinger, J., Ruzzenente, A., Schadde, E., Serenari, M., Sultana, A., Troisi, R., van Laarhoven, S., van Vugt, J. L. A., Surgery, Academic Medical Center, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Olthof, P. B., Aldrighetti, L., Alikhanov, R., Cescon, M., Groot Koerkamp, B., Jarnagin, W. R., Nadalin, S., Pratschke, J., Schmelze, M., Sparrelid, E., Lang, H., Guglielmi, A., van Gulik, T. M., Andreou, A., Bartsch, F., Benzing, C., Buettner, S., Capobianco, I., de Reuver, P., de Savornin Lohman, E., Dejong, C. H. C., Efanov, M., Erdmann, J. I., Franken, L. C., Frascaroli, G., Giglio, M. C., Gomez-Gavara, C., Heid, F., Ijzermans, J. N. M., Jansson, H., Ligthart, M. A. P., Maithel, S. K., Malago, M., Malik, H. Z., Muiesan, P., Olde Damink, S. W. M., Pando, E., Quinn, L. M., Ratti, F., Roberts, K. J., Rolinger, J., Ruzzenente, A., Schadde, E., Serenari, M., Sultana, A., Troisi, R., van Laarhoven, S., and van Vugt, J. L. A.

Subjects
Male, medicine.medical_specialty, medicine.medical_treatment, education, 030230 surgery, Preoperative care, Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14], 03 medical and health sciences, 0302 clinical medicine, Retrospective Studie, Preoperative Care, medicine, Hepatectomy, Humans, Embolization, Abscess, Bile Duct Neoplasm, Aged, Retrospective Studies, portal vein embolization, portal vein embolisation, Perihilar cholangiocarcinoma, Portal Vein, business.industry, Incidence (epidemiology), Liver Neoplasms, Correction, Retrospective cohort study, Middle Aged, Jaundice, medicine.disease, Embolization, Therapeutic, Surgery, Bile Duct Neoplasms, Oncology, Liver Neoplasm, Hepatobiliary Tumors, 030220 oncology & carcinogenesis, Propensity score matching, Cohort, medicine.symptom, business, Liver Failure, Human, Klatskin Tumor
Abstract

Background Preoperative portal vein embolization (PVE) is frequently used to improve future liver remnant volume (FLRV) and to reduce the risk of liver failure after major liver resection. Objective This paper aimed to assess postoperative outcomes after PVE and resection for suspected perihilar cholangiocarcinoma (PHC) in an international, multicentric cohort. Methods Patients undergoing resection for suspected PHC across 20 centers worldwide, from the year 2000, were included. Liver failure, biliary leakage, and hemorrhage were classified according to the respective International Study Group of Liver Surgery criteria. Using propensity scoring, two equal cohorts were generated using matching parameters, i.e. age, sex, American Society of Anesthesiologists classification, jaundice, type of biliary drainage, baseline FLRV, resection type, and portal vein resection. Results A total of 1667 patients were treated for suspected PHC during the study period. In 298 patients who underwent preoperative PVE, the overall incidence of liver failure and 90-day mortality was 27% and 18%, respectively, as opposed to 14% and 12%, respectively, in patients without PVE (p p = 0.005). After propensity score matching, 98 patients were enrolled in each cohort, resulting in similar baseline and operative characteristics. Liver failure was lower in the PVE group (8% vs. 36%, p p p = 0.01), and 90-day mortality (7% vs. 18%, p = 0.03). Conclusion PVE before major liver resection for PHC is associated with a lower incidence of liver failure, biliary leakage, abscess formation, and mortality. These results demonstrate the importance of PVE as an integral component in the surgical treatment of PHC.

Published
2020

47. Experiences of a multistep process with medical and psychological interventions for patients with congenital uterine aplasia to achieve motherhood: the Gothenburg–Tübingen collaboration

Author

Brucker, SY, Taran, F-A, Rall, K, Schöller, D, Dahm-Kâhler, P, Kvarnström, N, Järvholm, S, Nadalin, S, Königsrainer, A, Wallwiener, D, and Brännström, M

Subjects
laparoscopic-assisted neovagina, Review, congenital uterine and vaginal aplasia, uterus transplantation, MRKH-Syndrome, Vecchietti
Abstract

Congenital uterine aplasia, also known as Mayer-Rokitansky-Küster-Hauser syndrome (MRKHS) is a condition associated to a non-functional uterus in the presence of functional ovaries. In a setting where surrogacy is illegal (or not accepted) and adoption is the only alternative, neovaginoplasty and subsequent uterus transplantation (UTx) can provide a route to motherhood for women with MRKHS. This review article describes a multistep process by which patients with MRKHS can achieve motherhood with their own biological child. This process involving a careful clinical diagnosis, psychological counselling, assessment of eligibility for neovagina creation and UTx, the surgical treatment, fertility treatment, and long-term follow-up was developed at the Tübingen University Hospital and in close collaboration with Sahlgrenska Academy, University of Gothenburg, Sweden, where the basic experimental and clinical groundwork for UTx was laid and the first-ever UTx procedure was performed.

Published
2019

48. ASO Visual Abstract

Author

Ruzzenente, A., Bagante, F., Olthof, P.B., Aldrighetti, L., Alikhanov, R., Cescon, M., Koerkamp, B.G., Jarnagin, W.R., Nadalin, S., Pratschke, J., Schmelzle, M., Sparrelid, E., Lang, H., Iacono, C., van Gulik, T.M., Guglielmi, A., Andreou, A., Bartsch, F., Benzing, C., Buettner, S., Campagnaro, T., Capobianco, I., Charco, R., de Reuver, P., de Savornin Lohman, E., Dejong, C.H.C., Efanov, M., Erdmann, J.I., Franken, L.C., Giovinazzo, G., Giglio, M.C., Gomez-Gavara, C., Heid, F., Ijzermans, J.N.M., Isaac, J., Jansson, H., Ligthart, M.A.P., Maithel, S.K., Malago, M., Malik, H.Z., Muiesan, P., Damink, S.W.M.O., Quinn, L.M., Ratti, F., Ravaioli, M., Rolinger, J., Schadde, E., Serenari, M., Troisi, R., van Laarhoven, S., van Vugt, J.L.A., Surgery, CCA - Cancer Treatment and Quality of Life, and Amsterdam Gastroenterology Endocrinology Metabolism

Subjects
Intrahepatic, medicine.medical_specialty, business.industry, General surgery, MEDLINE, Cholangiocarcinoma, Collaborative group, Settore MED/18 - Chirurgia Generale, Oncology, Bile Duct Neoplasms, Surgical oncology, medicine, Humans, Surgery, Bile Ducts, Perihilar Cholangiocarcinoma, business, Bismuth, Bile Ducts, Intrahepatic, Klatskin Tumor
Published
2021

Catalog

Books, media, physical & digital resources
See catalog results